In short
Dorocubicel, an innovative drug being studied in clinical trials, offers hope for patients with high-risk acute leukemia and myelodysplasia. This article explores the ongoing research on Dorocubicel, which uses expanded cord blood transplantation to potentially improve outcomes for patients requiring allogeneic hematopoietic stem cell transplantation.
At a glance
- Drug Name
- Dorocubicel (ECT-001-CB)
- Trial Phase
- Phase II
- Target Condition
- High and very high-risk acute leukemia/myelodysplasia
- Main Objectives
- 1. Examine safety and feasibility of infusion; 2. Evaluate relapse-free survival at 1 and 2 years post-transplant
- Key Eligibility Criteria
- - High/very high-risk hematologic malignancy; - Availability of suitable cord blood units; - Specific health requirements for heart, lung, liver, and kidney function
- Administration
- Intravenous infusion
- Maximum Dose
- 7,500,000 cells per kg of body weight
- Secondary Endpoints
- - Hematopoietic engraftment kinetics; - Transplant-related mortality; - Incidence of GVHD; - Incidence of infectious complications; - Incidence of pre-engraftment/engraftment syndrome
What is DOROCUBICEL?
DOROCUBICEL, also known as ECT-001-CB, is an innovative medical treatment being studied for patients with high-risk blood cancers. It is a type of cell therapy that uses specially processed stem cells from umbilical cord blood. The technical name for this treatment is "UM171 dihydrobromide dihydrate expanded umbilical cord blood".
Medical Conditions Treated
DOROCUBICEL is being investigated for the treatment of high-risk and very high-risk acute leukemia and myelodysplasia. These are serious blood disorders that affect the production of healthy blood cells in the bone marrow. Patients with these conditions often require a stem cell transplant, also known as an allogeneic hematopoietic stem cell transplantation (HSCT), as part of their treatment.
How DOROCUBICEL Works
DOROCUBICEL is a combination of two components: Expanded cord blood cells (DOROCUBICEL): These are stem cells from umbilical cord blood that have been treated with a special molecule called UM171. This process helps increase the number of stem cells available for transplant. Non-expanded cord blood cells: These are additional stem cells from cord blood that haven't been expanded. Together, these components are designed to provide a more effective stem cell transplant for patients who need it.
Clinical Trial Details
DOROCUBICEL is currently being studied in a Phase II clinical trial. This means that while it has shown promise in earlier studies, it is still considered experimental and is not yet approved for widespread use. The main goals of this trial are to:
- Examine the safety and feasibility of using DOROCUBICEL in patients with high-risk blood cancers
- Evaluate how well patients do after receiving the treatment, particularly looking at relapse-free survival at 1 and 2 years after the transplant
Eligibility Criteria
Not everyone with leukemia or myelodysplasia is eligible for this trial. Some key eligibility criteria include:
- Having a high or very high-risk blood cancer that requires a stem cell transplant
- Meeting certain health requirements related to heart, lung, liver, and kidney function
- Not having had certain other treatments recently, such as another stem cell transplant within the last 6 months
- Not having active infections or other serious medical conditions
Potential Benefits
While the effectiveness of DOROCUBICEL is still being studied, researchers hope it may offer several potential benefits:
- Improved survival rates for patients with high-risk blood cancers
- Faster recovery of blood cell counts after transplant
- Reduced risk of transplant-related complications
- Potentially lower risk of graft-versus-host disease (GVHD), a common complication of stem cell transplants
Safety Considerations
As with any experimental treatment, there are potential risks and side effects associated with DOROCUBICEL. The clinical trial is designed to carefully monitor patients for:
- Graft failure (when the transplanted cells don't work properly)
- Infections
- Graft-versus-host disease (GVHD)
- Other transplant-related complications
It's important to note that participating in a clinical trial involves close monitoring by healthcare professionals to ensure patient safety and to gather important data about the treatment's effectiveness and potential side effects.